Results Identification of cyclohepta[ b ]indoles with GLP-1 releasing actions Using a three-component (4 + 3) annulation methodology developed by one of our groups (see Supplemental Material) 2 , we generated a library of cyclohepta[ b ]indoles (Fig
The, Empa-Kidney Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R
He also points to late-phase trials showing up to 22.7 percent weight loss when a different amylin-based drug in development (cagrilintide) is used in combination with a GLP-1 (semaglutide)
Clinical translation requires the following elements: cross-regional, multicenter validation in at least three independent cohorts with population heterogeneity
Phytomedicine 120 , 155071 (2023)
Avoid alcohol, NSAIDs (e.g., aspirin, ibuprofen), or blood-thinning supplements 48 hours before treatment unless prescribed